{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T23:09:28Z","timestamp":1721171368624},"reference-count":37,"publisher":"Impact Journals, LLC","issue":"19","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2016,5,10]]},"DOI":"10.18632\/oncotarget.8760","type":"journal-article","created":{"date-parts":[[2016,4,16]],"date-time":"2016-04-16T08:50:23Z","timestamp":1460796623000},"page":"28684-28696","source":"Crossref","is-referenced-by-count":8,"title":["Hsp90 inhibition increases SOCS3 transcript and regulates migration and cell death in chronic lymphocytic leukemia"],"prefix":"10.18632","volume":"7","author":[{"given":"Timothy L.","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Division of Hematology, Comprehensive Cancer Center at The Ohio State University, Columbus, Ohio, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikhil","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Hematology, Comprehensive Cancer Center at The Ohio State University, Columbus, Ohio, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Lehman","sequence":"additional","affiliation":[{"name":"Center for Biostatistics, The Ohio State University, Columbus, Ohio, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy S.","family":"Ruppert","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Hematology, Comprehensive Cancer Center at The Ohio State University, Columbus, Ohio, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lianbo","family":"Yu","sequence":"additional","affiliation":[{"name":"Center for Biostatistics, The Ohio State University, Columbus, Ohio, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher C.","family":"Oakes","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Hematology, Comprehensive Cancer Center at The Ohio State University, Columbus, Ohio, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rainer","family":"Claus","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Stem Cell Transplantation, University Medical Center Freiburg, Freiburg, Germany"},{"name":"Division of Epigenomics and Cancer Risk Factors, German Cancer Research Center, Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Plass","sequence":"additional","affiliation":[{"name":"Division of Epigenomics and Cancer Risk Factors, German Cancer Research Center, Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kami J.","family":"Maddocks","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Hematology, Comprehensive Cancer Center at The Ohio State University, Columbus, Ohio, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leslie","family":"Andritsos","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Hematology, Comprehensive Cancer Center at The Ohio State University, Columbus, Ohio, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffery A.","family":"Jones","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Hematology, Comprehensive Cancer Center at The Ohio State University, Columbus, Ohio, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Lucas","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Hematology, Comprehensive Cancer Center at The Ohio State University, Columbus, Ohio, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy J.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Hematology, Comprehensive Cancer Center at The Ohio State University, Columbus, Ohio, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John C.","family":"Byrd","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Hematology, Comprehensive Cancer Center at The Ohio State University, Columbus, Ohio, USA"},{"name":"Division of Medicinal Chemistry & Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, Ohio, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin","family":"Hertlein","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Hematology, Comprehensive Cancer Center at The Ohio State University, Columbus, Ohio, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2016,4,16]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"13433","DOI":"10.1073\/pnas.0906455106","article-title":"Epigenetic changes during disease progression in a murine model of human chronic lymphocytic leukemia","volume":"106","author":"Davuluri","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1365-2141.2010.08213.x","article-title":"Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence of DNA hypomethylation","volume":"150","author":"Byrd","year":"2010","journal-title":"Br J Haematol"},{"key":"3","first-page":"121","article-title":"Signalling to drug resistance in CLL","volume":"23","author":"Byrd","journal-title":"Best Pract Res Clin Haematol"},{"key":"4","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1517\/14728221003598930","article-title":"NF-kappaB as a therapeutic target in chronic lymphocytic leukemia","volume":"14","author":"Colomer","year":"2010","journal-title":"Expert Opin Ther Targets"},{"key":"5","doi-asserted-by":"crossref","first-page":"7065","DOI":"10.1128\/MCB.21.20.7065-7077.2001","article-title":"The p65 (RelA) subunit of NF-kappaB interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression","volume":"21","author":"Baldwin","year":"2001","journal-title":"Mol Cell Biol"},{"key":"6","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.jhep.2010.03.025","article-title":"The NF-kappaB p50:p50:HDAC-1 repressor complex orchestrates transcriptional inhibition of multiple pro-inflammatory genes","volume":"53","author":"Mann","year":"2010","journal-title":"J Hepatol"},{"key":"7","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1023\/B:MCBI.0000044394.66951.4d","article-title":"The p50-p50 NF-kappaB complex as a stimulus-specific repressor of gene activation","volume":"265","author":"Giardina","year":"2004","journal-title":"Mol Cell Biochem"},{"key":"8","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1101\/gad.1657408","article-title":"Repression of gene expression by unphosphorylated NF-kappaB p65 through epigenetic mechanisms","volume":"22","author":"Ghosh","year":"2008","journal-title":"Genes Dev"},{"key":"9","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2010-01-263756","article-title":"17-DMAG targets the nuclear factor-kappaB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition","volume":"116","author":"Johnson","year":"2010","journal-title":"Blood"},{"key":"10","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.3109\/10428194.2011.647310","article-title":"The Hsp90 inhibitor SNX-7081 synergizes with and restores sensitivity to fludarabine in chronic lymphocytic leukemia cells with lesions in the TP53 pathway: a potential treatment strategy for fludarabine refractory disease","volume":"53","author":"Mulligan","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"11","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.3109\/10428194.2012.698278","article-title":"Heat shock protein-90 inhibitor, NVP-AUY922, is effective in combination with fludarabine against chronic lymphocytic leukemia cells cultured on CD40L-stromal layer and inhibits their activated\/proliferative phenotype","volume":"53","author":"Mulligan","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"12","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1111\/j.1365-2141.2007.06878.x","article-title":"Rituximab and 17-allylamino-17-demethoxygeldanamycin induce synergistic apoptosis in B-cell chronic lymphocytic leukaemia","volume":"139","author":"Byrd","year":"2007","journal-title":"Br J Haematol"},{"key":"13","doi-asserted-by":"publisher","first-page":"525","DOI":"10.18632\/oncotarget.491","article-title":"The Hsp90 inhibitor NVP-AUY922-AG inhibits NF-kappaB signaling, overcomes microenvironmental cytoprotection and is highly synergistic with fludarabine in primary CLL cells","volume":"3","author":"Pepper","year":"2012","journal-title":"Oncotarget"},{"key":"14","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/j.1365-2141.2008.07072.x","article-title":"Epigenetic inactivation of suppressors of cytokine signalling in Philadelphia-negative chronic myeloproliferative disorders","volume":"141","author":"Lunghi","year":"2008","journal-title":"Br J Haematol"},{"key":"15","doi-asserted-by":"crossref","first-page":"14133","DOI":"10.1073\/pnas.2232790100","article-title":"SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer","volume":"100","author":"Jablons","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"16","doi-asserted-by":"crossref","first-page":"7726","DOI":"10.1038\/sj.onc.1207787","article-title":"Differential hypermethylation of SOCS genes in ovarian and breast carcinomas","volume":"23","author":"Visvader","year":"2004","journal-title":"Oncogene"},{"key":"17","first-page":"689","article-title":"Methylation status of the SOCS3 gene in human malignant melanomas","volume":"30","author":"Masuda","year":"2007","journal-title":"Int J Oncol"},{"key":"18","doi-asserted-by":"crossref","first-page":"e76607","DOI":"10.1371\/journal.pone.0076607","article-title":"Characterization of a New Chronic Lymphocytic Leukemia Cell Line for Mechanistic and Studies Relevant to Disease","volume":"8","author":"Croce","year":"2013","journal-title":"PLoS One"},{"key":"19","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1038\/sj.onc.1201403","article-title":"Effects of the inhibition of p38\/RK MAP kinase on induction of five fos and jun genes by diverse stimuli","volume":"15","author":"Mahadevan","year":"1997","journal-title":"Oncogene"},{"key":"20","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1210\/me.2007-0030","article-title":"Characterization of the SOCS3 promoter response to prostaglandin E2 in T47D cells","volume":"21","author":"Curlewis","year":"2007","journal-title":"Mol Endocrinol"},{"key":"21","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.4049\/jimmunol.174.5.2494","article-title":"Cutting edge: IL-4 induces suppressor of cytokine signaling-3 expression in B cells by a mechanism dependent on activation of p38 MAPK","volume":"174","author":"Rothman","year":"2005","journal-title":"J Immunol"},{"key":"22","first-page":"650812","article-title":"SOCS3 expression correlates with severity of inflammation, expression of proinflammatory cytokines, and activation of STAT3 and p38 MAPK in LPS-induced inflammation","volume":"2013","author":"Rossa","year":"2013","journal-title":"Mediators Inflamm"},{"key":"23","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/j.1365-2141.2010.08443.x","article-title":"OSU-DY7, a novel D-tyrosinol derivative, mediates cytotoxicity in chronic lymphocytic leukaemia and Burkitt lymphoma through p38 mitogen-activated protein kinase pathway","volume":"153","author":"Muthusamy","year":"2011","journal-title":"Br J Haematol"},{"key":"24","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1182\/blood.V99.4.1314","article-title":"The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism","volume":"99","author":"Jurlander","year":"2002","journal-title":"Blood"},{"key":"25","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1080\/1042819021000029984","article-title":"Flavopiridol induces apoptosis in B-cell chronic lymphocytic leukaemia cells through a p38 and ERK MAP kinase-dependent mechanism","volume":"44","author":"Bentley","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"26","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.immuni.2007.09.011","article-title":"SOCS3 protein developmentally regulates the chemokine receptor CXCR4-FAK signaling pathway during B lymphopoiesis","volume":"27","author":"Silberstein","year":"2007","journal-title":"Immunity"},{"key":"27","doi-asserted-by":"crossref","first-page":"6406","DOI":"10.1038\/sj.onc.1208788","article-title":"Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK\/STAT and FAK signalings in human hepatocellular carcinoma","volume":"24","author":"Yoshikawa","year":"2005","journal-title":"Oncogene"},{"key":"28","doi-asserted-by":"crossref","first-page":"3928","DOI":"10.1182\/blood-2006-02-006353","article-title":"SOCS up-regulation mobilizes autologous stem cells through CXCR4 blockade","volume":"108","author":"Mellado","year":"2006","journal-title":"Blood"},{"key":"29","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/iub.607","article-title":"STAT3 interacts directly with Hsp90","volume":"64","author":"Blatch","year":"2012","journal-title":"IUBMB Life"},{"key":"30","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1038\/sj.leu.2403544","article-title":"Constitutive activation of the MAPkinase p38 is critical for MMP-9 production and survival of B-CLL cells on bone marrow stromal cells","volume":"18","author":"Decker","year":"2004","journal-title":"Leukemia"},{"key":"31","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1186\/1471-2407-12-478","article-title":"Phospho-specific flow cytometry identifies aberrant signaling in indolent B-cell lymphoma","volume":"12","author":"Kolstad","year":"2012","journal-title":"BMC Cancer"},{"key":"32","doi-asserted-by":"crossref","first-page":"4835","DOI":"10.4049\/jimmunol.1003050","article-title":"CD5 promotes IL-10 production in chronic lymphocytic leukemia B cells through STAT3 and NFAT2 activation","volume":"186","author":"Youinou","year":"2011","journal-title":"J Immunol"},{"key":"33","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.immuni.2006.11.012","article-title":"Bruton's tyrosine kinase and phospholipase Cgamma2 mediate chemokine-controlled B cell migration and homing","volume":"26","author":"Spaargaren","year":"2007","journal-title":"Immunity"},{"key":"34","doi-asserted-by":"crossref","first-page":"e11716","DOI":"10.1371\/journal.pone.0011716","article-title":"Elucidating the CXCL12\/CXCR4 signaling network in chronic lymphocytic leukemia through phosphoproteomics analysis","volume":"5","author":"Handel","year":"2010","journal-title":"PLoS One"},{"key":"35","doi-asserted-by":"crossref","first-page":"e48929","DOI":"10.1371\/journal.pone.0048929","article-title":"Dasatinib inhibits CXCR4 signaling in chronic lymphocytic leukaemia cells and impairs migration towards CXCL12","volume":"7","author":"Michie","year":"2012","journal-title":"PLoS One"},{"key":"36","first-page":"251479","article-title":"Immunohistochemical analysis of IL-6, IL-8\/CXCR2 axis, Tyr p-STAT-3, and SOCS-3 in lymph nodes from patients with chronic lymphocytic leukemia: correlation between microvascular characteristics and prognostic significance","volume":"2014","author":"Angelopoulou","year":"2014","journal-title":"Biomed Res Int"},{"key":"37","doi-asserted-by":"crossref","first-page":"4990","DOI":"10.1182\/blood.V87.12.4990.bloodjournal87124990","article-title":"National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment","volume":"87","author":"Rai","year":"1996","journal-title":"Blood"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.8760","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T20:16:34Z","timestamp":1718482594000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.8760"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,16]]},"references-count":37,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2016,5,10]]}},"alternative-id":["8760","27107422"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.8760","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,16]]}}}